Equities research analysts expect that BioDelivery Sciences International, Inc. (NASDAQ:BDSI) will post earnings per share of ($0.06) for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for BioDelivery Sciences International’s earnings, with the highest EPS estimate coming in at ($0.01) and the lowest estimate coming in at ($0.25). BioDelivery Sciences International posted earnings of ($0.16) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 62.5%. The business is expected to issue its next quarterly earnings report on Thursday, August 8th.
According to Zacks, analysts expect that BioDelivery Sciences International will report full-year earnings of ($0.14) per share for the current financial year, with EPS estimates ranging from ($0.42) to ($0.05). For the next financial year, analysts expect that the company will report earnings of $0.25 per share, with EPS estimates ranging from $0.09 to $0.46. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that follow BioDelivery Sciences International.
BioDelivery Sciences International (NASDAQ:BDSI) last announced its quarterly earnings data on Monday, May 6th. The specialty pharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.03. The firm had revenue of $19.77 million during the quarter, compared to the consensus estimate of $19.60 million. BioDelivery Sciences International had a negative return on equity of 43.40% and a negative net margin of 42.09%.
BioDelivery Sciences International stock traded down $0.05 during mid-day trading on Wednesday, hitting $4.30. The company’s stock had a trading volume of 20,517 shares, compared to its average volume of 743,186. The stock’s 50 day moving average is $4.50. The firm has a market cap of $392.95 million, a P/E ratio of -5.90 and a beta of 0.47. The company has a current ratio of 2.88, a quick ratio of 2.57 and a debt-to-equity ratio of 1.90. BioDelivery Sciences International has a 52-week low of $2.35 and a 52-week high of $5.37.
In related news, Director Mark A. Sirgo sold 484,752 shares of the firm’s stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $4.22, for a total value of $2,045,653.44. Following the transaction, the director now directly owns 2,559,803 shares of the company’s stock, valued at approximately $10,802,368.66. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Healthcare Master Fun Broadfin sold 2,000,000 shares of the firm’s stock in a transaction that occurred on Thursday, April 11th. The shares were sold at an average price of $5.00, for a total value of $10,000,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 4,339,037 shares of company stock valued at $21,313,438 over the last ninety days. Company insiders own 8.94% of the company’s stock.
Hedge funds have recently modified their holdings of the stock. Advisor Group Inc. raised its stake in shares of BioDelivery Sciences International by 56.3% in the 4th quarter. Advisor Group Inc. now owns 10,943 shares of the specialty pharmaceutical company’s stock valued at $40,000 after acquiring an additional 3,943 shares in the last quarter. First Allied Advisory Services Inc. acquired a new stake in BioDelivery Sciences International in the 1st quarter valued at approximately $58,000. Means Investment CO. Inc. acquired a new stake in BioDelivery Sciences International in the 1st quarter valued at approximately $59,000. QCM Cayman Ltd. acquired a new stake in BioDelivery Sciences International in the 1st quarter valued at approximately $35,000. Finally, Close Asset Management Ltd grew its holdings in BioDelivery Sciences International by 1,340.0% in the 1st quarter. Close Asset Management Ltd now owns 18,000 shares of the specialty pharmaceutical company’s stock valued at $95,000 after buying an additional 16,750 shares during the last quarter. 56.73% of the stock is currently owned by institutional investors and hedge funds.
BioDelivery Sciences International Company Profile
BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.